Table 2.
Recovery and matrix effect data.
| Analyte | Recovery (%)a | RSD (%)a | Ion supression (%) ± SD (%) in matrixb |
|---|---|---|---|
| AC-262536 | 83 | 8.9 | 20.1 ± 12.8 |
| Andarine | 89 | 7.9 | 26.2 ± 9.2 |
| Bicalutamide | 85 | 10.6 | 21.5 ± 12.5 |
| BMS-564929 | 99 | 10.9 | 54 ± 6.5 |
| GLPG0492 | 93 | 7.3 | 36.6 ± 8.9 |
| LGD-2226 | 87 | 11.7 | 25.3 ± 15.5 |
| LGD-4033 | 93 | 7.3 | 28.7 ± 14.4 |
| Ly2452473 | 91 | 7.5 | 21.3 ± 14.3 |
| Ostarine | 87 | 8.2 | 9.5 ± 16.2 |
| PF-06260414 | 100 | 11.0 | 39.8 ± 7.2 |
| RAD140 | 92 | 9.0 | 46.0 ± 10.6 |
| S-1 | 87 | 8.9 | 29.1 ± 18.8 |
| S-6 | 81 | 12.0 | 26.9 ± 24.9 |
| S-9 | 82 | 10.2 | 28.9 ± 22.9 |
| S-23 | 83 | 9.0 | 24.6 ± 22.9 |
a
Recovery was determined by comparing results from fortified samples to those of negative samples spiked post-extraction at the screening target concentration (Cval). Recovery is based on data collected from six analytical runs.
b
Ion suppression results for urine matrices are based on the analysis of 12 samples from different sources. Values calculated as described in Section 2.6.